Oral nuclear factor-κB decoy oligonucleotides delivery system with chitosan modified poly(d,l-lactide-co-glycolide) nanospheres for inflammatory bowel disease

Biomaterials

Volumn 32, Issue 3, 2011, Pages 870-878

  Tahara, Kohei ^a,b   Samura, Sota ^a   Tsuji, Kaori ^a   Yamamoto, Hiromitsu ^a   Tsukada, Yusuke ^c   Bando, Yohei ^c   Tsujimoto, Hiroyuki ^c   Morishita, Ryuichi ^d   Kawashima, Yoshiaki ^a  

^a AICHI GAKUIN UNIVERSITY   (Japan)

^b NAGOYA CITY UNIVERSITY   (Japan)

^c HOSOKAWA MICRON CORPORATION   (Japan)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

Chitosan; Nanosphere; NF kB decoy oligonucleotide; Oral delivery system; Poly(d,l lactide co glycolide); Ulcerative colitis

Indexed keywords

ACIDIC MEDIUMS; CACO-2 CELLS; CONFOCAL LASER SCANNING MICROSCOPY; DELIVERY SYSTEMS; DEXTRAN SULFATE SODIUM; EMULSION SOLVENT DIFFUSION METHOD; EXPERIMENTAL MODELS; GASTRIC JUICE; GLYCOLIDE; INFLAMMATORY BOWEL DISEASE; L-LACTIDE; MUCOSAL TISSUES; MYELOPEROXIDASE; NF-KB DECOY OLIGONUCLEOTIDE; NUCLEAR FACTOR KAPPAB; NUCLEAR FACTORS; ORAL ADMINISTRATION; ORAL DELIVERY; PHYSICOCHEMICAL PROPERTY; POLY(D ,L-LACTIDE-CO- GLYCOLIDE); RAT MODEL; ULCERATIVE COLITIS;

CHITIN; CHITOSAN; CONFOCAL MICROSCOPY; EMULSIFICATION; GLUCOSE; NANOSPHERES; OLIGONUCLEOTIDES; SODIUM; SODIUM SULFATE; ZETA POTENTIAL;

ORGANIC POLYMERS;

CHITOSAN; DECOY OLIGONUCLEOTIDE; DEOXYRIBONUCLEASE I; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYELOPEROXIDASE; NANOSPHERE; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; POLYGLACTIN; UNCLASSIFIED DRUG;

ACIDITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL STRAIN CACO 2; CHEMICAL MODIFICATION; COLON; DIARRHEA; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG STABILITY; EMULSION; ENZYME ACTIVITY; OCCULT BLOOD; OLIGONUCLEOTIDE THERAPY; PARTICLE SIZE; PRIORITY JOURNAL; ULCERATIVE COLITIS; ZETA POTENTIAL;

ANIMALS; CHITOSAN; DRUG CARRIERS; INFLAMMATORY BOWEL DISEASES; LACTIC ACID; MALE; NANOSPHERES; NF-KAPPA B; OLIGONUCLEOTIDES; POLYGLYCOLIC ACID; RATS; RATS, WISTAR;

RATTUS;

EID: 78549254833     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.09.034     Document Type: Article

References (29)

1. Lamprecht A., Stallmach A., Kawashima Y., Lehr C.M. Carrier systems for the treatment of inflammatory bowel disease. Drugs Fut 2002, 27:961-971.
2. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 2002, 347:417-429.
3. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104.
4. Reinecker H.C., Steffen M., Witthoeft T., Pflueger I., Schreiber S., MacDermott R.P., et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993, 94:174-181.
5. Morishita R., Tomita N., Kaneda Y., Ogihara T. Molecular therapy to inhibit NFkappaB activation by transcription factor decoy oligonucleotides. Curr Opin Pharmacol 2004, 4:139-146.
6. Morishita R., Sugimoto T., Aoki M., Kida I., Tomita N., Moriguchi A., et al. In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 1997, 3:894-899.
7. Fichtner-Feigl S., Fuss I.J., Preiss J.C., Strober W., Kitani A. Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides. J Clin Invest 2005, 115:3057-3071.
8. De Vry C.G., Prasad S., Komuves L., Lorenzana C., Parham C., Le T., et al. Non-viral delivery of nuclear factor-kappaB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis. Gut 2007, 56:524-533.
9. Xiang J.Y., Wu L.G., Huang X.L., Zhang M., Pen L., Ouyan Q., et al. Amelioration of murine dextran sulfate sodium-induced colitis by nuclear factor-kappaB decoy oligonucleotides. Am J Surg 2009, 197:797-805.
10. Bhavsar M.D., Amiji M.M. Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther 2008, 15:1200-1209.
11. Roy K., Mao H.Q., Huang S.K., Leong K.W. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999, 5:387-391.
12. Vasir J.K., Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev 2007, 59:718-728.
13. Panyam J., Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003, 55:329-347.
14. Okada H. One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv Drug Deliv Rev 1997, 28:43-70.
15. Tahara K., Yamamoto H., Takeuchi H., Kawashima Y. Development of gene delivery system using PLGA nanospheres. Yakugaku Zasshi 2007, 127:1541-1548.
16. Tahara K., Yamamoto H., Hirashima N., Kawashima Y. Chitosan-modified poly(D, L-lactide-co-glycolide) nanospheres for improving siRNA delivery and gene-silencing effects. Eur J Pharm Biopharm 2010, 74:421-426.
17. Kawashima Y., Yamamoto H., Takeuchi H., Kuno Y. Mucoadhesive DL-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. Pharm Dev Technol 2000, 5:77-85.
18. Tahara K., Sakai T., Yamamoto H., Takeuchi H., Kawashima Y. Establishing chitosan coated PLGA nanosphere platform loaded with wide variety of nucleic acid by complexation with cationic compound for gene delivery. Int J Pharm 2008, 354:210-216.
19. Rumi G., Tsubouchi R., Nishio H., Kato S., Mozsik G., Takeuchi K. Dual role of endogenous nitric oxide in development of dextran sodium sulfate-induced colitis in rats. J Physiol Pharmacol 2004, 55:823-836.
20. Krawisz J.E., Sharon P., Stenson W.F. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984, 87:1344-1350.
21. Niven R., Zhang Y., Smith J. Toward development of a non-viral gene therapeutic. Adv Drug Deliv Rev 1997, 26:135-150.
22. Matsuda N., Hattori Y., Jesmin S., Gando S. Nuclear factor-kappaB decoy oligodeoxynucleotides prevent acute lung injury in mice with cecal ligation and puncture-induced sepsis. Mol Pharmacol 2005, 67:1018-1025.
23. Griesenbach U., Cassady R.L., Cain R.J., duBois R.M., Geddes D.M., Alton E.W. Cytoplasmic deposition of NFkappaB decoy oligonucleotides is insufficient to inhibit bleomycin-induced pulmonary inflammation. Gene Ther 2002, 9:1109-1115.
24. Higuchi Y., Kawakami S., Oka M., Yabe Y., Yamashita F., Hashida M. Intravenous administration of mannosylated cationic liposome/NFkappaB decoy complexes effectively prevent LPS-induced cytokine production in a murine liver failure model. FEBS Lett 2006, 580:3706-3714.
25. Tahara K., Sakai T., Yamamoto H., Takeuchi H., Hirashima N., Kawashima Y. Improved cellular uptake of chitosan-modified PLGA nanospheres by A549 cells. Int J Pharm 2009, 382:198-204.
26. Lv H., Zhang S., Wang B., Cui S., Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 2006, 114:100-109.
27. Elson C.O., Sartor R.B., Tennyson G.S., Riddell R.H. Experimental models of inflammatory bowel disease. Gastroenterology 1995, 109:1344-1367.
28. Lamprecht A., Yamamoto H., Takeuchi H., Kawashima Y. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J Pharmacol Exp Ther 2005, 315:196-202.
29. Tabata Y., Inoue Y., Ikada Y. Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine 1996, 14:1677-1685.